Boehringer Ingelheim ranked among the 100 leading global innovators by Thomson Reuters

Ingelheim, 20-11-2015 — /EuropaWire/ — Boehringer Ingelheim has been named one of the most innovative companies worldwide in 2015. For the first time, the research-driven pharmaceutical company ranked among the 100 leading global innovators named by news agency Thomson Reuters.

Thomson Reuters has granted this award since 2011. To measure innovative strength and determine the winners, the news agency pursued a detailed scientific approach based on four principle criteria: overall patent volume, patent application-to-grant success rate, global reach of the portfolio, and patent influence as evidenced by citations.

For further information go to http://www.stateofinnovation.com.

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

MEDIA CONTACT

Boehringer Ingelheim

Media & PR
Julia Löffelsend
Binger Strasse 173
55216 Ingelheim am Rhein
GERMANY
Phone +49/6132/77 143548
Fax +49/6132/77 6601
e-mail